Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mocravimod - Priothera

Next Previous
Drug Profile

Mocravimod - Priothera

Alternative Names: KRP-203

Latest Information Update: 30 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Kyorin Pharmaceutical; Novartis; Priothera
  • Class Anti-inflammatories; Propylene glycols
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Cutaneous lupus erythematosus; Ulcerative colitis

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Crohn's disease; Cutaneous lupus erythematosus; Ulcerative colitis
  • Phase I/II Diffuse large B cell lymphoma

Most Recent Events

  • 24 Jun 2025 Priothera plans a MOCART clinical trial trial for Acute myeloid leukemia
  • 27 Nov 2023 Mocravimod receives Orphan Drug status for improvement of the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies in USA
  • 05 Jun 2023 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater) in Germany (PO) (EudraCT2022-003618-35)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top